Phaseline

Targets › RIPA

RIPA: drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 4, 1 Phase 1; Infectious disease.

Open in Phaseline: the race on RIPA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Aurum Institute NPCRifapentine
Bacterial DNA-directed RNA polymerase inhibitor
RIPA, INH, UNKNOWNPhase 4HIV Seropositivity–

Conditions

HIV Seropositivity (3)

Modalities

small molecule (1)

Companies

The Aurum Institute NPC (1)

Related targets

INH (1) UNKNOWN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.